Harvey Berger

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Harvey Berger
Harvey Berger M.D.jpg
Born (1950-06-06) June 6, 1950 (age 69)
Alma materColgate University (1972, B.A.)
Yale School of Medicine (1977, M.D.)
OccupationExecutive Chairman at Medinol, Inc.
Board member ofDana-Farber Cancer Institute

Harvey J. Berger, M.D. is an American physician-scientist, entrepreneur, philanthropist, and biotechnology executive. He is the founder, chairman and CEO emeritus of ARIAD Pharmaceuticals, Inc. and executive chairman at Medinol, Inc.

Early life and education[edit]

Berger received his B.A. in Biology from Colgate University in 1972 and received his M.D. from Yale School of Medicine in 1977.[1][2] He completed further medical and research training at the Massachusetts General Hospital and Yale-New Haven Hospital.[2]

Career[edit]

From 1986 until 1991, Berger held executive management positions at Centocor, Inc. including executive vice president and president of the Research and Development Division.[3] He led the development of Remicade® (infliximab), formerly known as Centara, a drug for the treatment of autoimmune diseases such as Crohn's disease, ulcerative colitis and rheumatoid arthritis, ReoPro® (abciximab), formerly known as CentoRx, a drug for the prevention of ischemic complications in patients with CAD undergoing percutaneous interventions,[4][5] and the cancer diagnostic test, CA125, to evaluate patients with ovarian cancer.[6][7]

In 1991, Berger founded ARIAD Pharmaceuticals in Cambridge, Massachusetts.[8][9] He served as chairman and CEO from 1991 to 2015.[9][2] In 1992, ARIAD raised $46 million, the largest single round of financing for a startup in the biotechnology industry at the time.[10][11] ARIAD's plan was to develop drugs that would interfere with communication signals within cells, rather than on the cell surface or in between cells.[10] In 1994, ARIAD filed for an initial public offering and was listed on the NASDAQ market.[12][13]

In 2000, Berger focused ARIAD on oncology, based on recent discoveries in the human genome.[11][14] Under Berger's leadership, ARIAD grew to over 365 employees and established a European headquarters in Lausanne, Switzerland.[15][16]

While Berger was CEO, ARIAD developed five new medicines including the blood-cancer drug Iclusig, Brigatinib, a potential lung cancer treatment and AP37288, for lung cancer with novel mutated genetic targets.[9][17]

At the end of 2015, Berger retired from ARIAD and became an advisor to the board of directors.[9][18] In early 2017, ARIAD was acquired by Takeda Pharmaceuticals, Ltd. for $5.2 billion, becoming part of Takeda Oncology.[19]

In February 2017, Medinol, Inc. announced that Berger would be serving as its executive chairman.[20] On the global management team, his focuses at Medinol would include business management, global strategy, new business and technology initiatives, as well as improving operational efficiency as the company expands worldwide.[21][3] Berger's role at Medinol was said to include working with their core business of interventional cardiovascular devices, along with its new businesses developing percutaneous aortic valves, sub-millimeter implantable sensors, and related products.[21]

Berger has held senior academic and administrative roles at Emory University, Yale University and the University of Pennsylvania.[3][21] He was also a member of the Dean's Council of Yale University School of Medicine.[2] During his time at Emory, Berger led a program for developing cardiovascular single-photon emission computed tomographic (SPECT) imaging, supported by General Electric Medical Systems.[22] He and other colleagues at Emory collaborated on the development of new quantitative techniques for cardiac SPECT imaging.[23]

Berger has contributed to a wide range of medical journals including the New England Journal of Medicine and American Journal of Cardiology,[24][25] and has been interviewed by Fox Business[26][27][28][29] and CNBC.[30] He was also an established investigator of the American Heart Association.[3]

Awards[edit]

In 2013, Berger was awarded the Ernst & Young Entrepreneur of the Year Award for the New England Region. The award recognizes success in innovation, financial performance, personal commitment to their business communities and other areas.[31] In the same year, Berger was awarded the Gold Stevie Award as Executive of the Year, Pharmaceuticals.[32][33]

Personal life and philanthropy[edit]

Berger resides in Palm Beach, Florida, with his wife Chrysanthi and their two daughters, Isabella Grace Berger and Nicole Elizabeth Berger.[34][35] His daughter Nicole has appeared in several movies including Two for One.[36] Chrysanthi Berger (née Casseres)[37] attended Laguardia High School of Music and Art and was the concertmaster there. She earned a master's degree from the Manhattan School of Music.[38]

Harvey and Chrysanthi Berger have supported the Palm Beach Day Academy and the American Cancer Society.[39][40] In February 2018, Berger was appointed to the Dana-Farber Cancer Institute Board of Trustees, the governing board of the organization.[41]

References[edit]

  1. ^ "A showcase of alumni talent (The Colgate Scene, September 2002)". www4.colgate.edu. Retrieved 2017-09-25.
  2. ^ a b c d "MIT Sloan BioInnovations 2011". web.mit.edu. Retrieved 2017-09-20.
  3. ^ a b c d Bader, Emily (2017-02-16). "Medinol appoints executive chairman of Medinol US | NJBIZ". NJBIZ. Retrieved 2017-09-23.
  4. ^ Letter, The Pharma. "US Approval For Centocor's ReoPro – Pharmaceutical industry news". www.thepharmaletter.com. Retrieved 2017-09-25.
  5. ^ "Biotechnology Report, Medicines in Development, 2006 | Interleukin 2 | Monoclonal Antibody". Scribd. Retrieved 2017-09-25.
  6. ^ "Centocor CA 125 II, New Version of CA 125 Assay, Is Now Available | Cancer Network". www.cancernetwork.com. Retrieved 2018-03-20.
  7. ^ Matsukura, A.; Nakazawa, Y.; Hama, S. (November 1989). "[A shortened method for the assay with Centocor radioimmunoassay kit]". Radioisotopes. 38 (11): 469–472. doi:10.3769/radioisotopes.38.11_469. ISSN 0033-8303. PMID 2595020.
  8. ^ "Ariad moving to new Kendall Square headquarters – The Boston Globe". BostonGlobe.com. Retrieved 2017-09-24.
  9. ^ a b c d "Former Ariad CEO Berger says Takeda deal was 'merely a matter of time'". www.bizjournals.com. Retrieved 2017-09-24.
  10. ^ a b Pollack, Rew (1992-03-27). "COMPANY NEWS; Ariad Raises $46 Million In Placement". The New York Times. ISSN 0362-4331. Retrieved 2017-09-25.
  11. ^ a b "ARIAD Pharmaceuticals | Stevie Awards". stevieawards.com. Retrieved 2017-09-25.
  12. ^ "Equity Issues This Week". The New York Times. 1994-05-16. ISSN 0362-4331. Retrieved 2017-09-25.
  13. ^ "Ariad Pharmaceuticals, Inc. (ARIA) Stock Higher on Takeda Buyout News". NASDAQ.com. 2017-01-09. Retrieved 2017-09-25.
  14. ^ "Interview: Harvey Berger and Timothy Clackson, Ariad". www.pmlive.com. 2013-10-14. Retrieved 2017-09-20.
  15. ^ "Ariad's Harvey Berger says he's 'absolutely' secure in his role as CEO". www.bizjournals.com. Retrieved 2017-09-25.
  16. ^ "Ariad sells European operations for $140M upfront plus royalties". www.bizjournals.com. Retrieved 2017-09-25.
  17. ^ "Positive Preclinical Results for Lung Cancer Drug Announced at Annual Meeting of Cancer Research – Lung Disease News". Lung Disease News. 2016-04-22. Retrieved 2017-09-24.
  18. ^ "ARIAD Founder, Harvey J. Berger, M.D., to Retire as Chairman and Chief Executive Officer". ARIAD Pharmaceuticals, Inc. Retrieved 2017-09-24.
  19. ^ "Former Ariad CEO Berger says Takeda deal was 'merely a matter of time'". www.bizjournals.com. Retrieved 2017-09-23.
  20. ^ "Berger named to post at Medinol – The Boston Globe". BostonGlobe.com. Retrieved 2017-09-25.
  21. ^ a b c "Medinol hires Harvey Berger as executive chairman of its US operations". Cardiovascular Business. Retrieved 2017-09-23.
  22. ^ DePasquale, E. E.; Nody, A. C.; DePuey, E. G.; Garcia, E. V.; Pilcher, G.; Bredlau, C.; Roubin, G.; Gober, A.; Gruentzig, A. (1988-02-01). "Quantitative rotational thallium-201 tomography for identifying and localizing coronary artery disease". Circulation. 77 (2): 316–327. doi:10.1161/01.CIR.77.2.316. ISSN 0009-7322. PMID 3257422.
  23. ^ Berger, Harvey J.; Eisner, Robert; DePuey, E. Gordon; Patterson, Randolph (1984-11-01). "New Vistas in Cardiovascular Nuclear Medicine". Journal of Nuclear Medicine. 25 (11): 1254–1258. ISSN 0161-5505. PMID 6333498.
  24. ^ Ziegler, Elizabeth J.; Fisher, Charles J.; Sprung, Charles L.; Straube, Richard C.; Sadoff, Jerald C.; Foulke, Garrett E.; Wortel, Cornelis H.; Fink, Mitchell P.; Dellinger, R. Phillip (1991). "Treatment of Gram-Negative Bacteremia and Septic Shock with HA-1A Human Monoclonal Antibody against Endotoxin". New England Journal of Medicine. 324 (7): 429–436. doi:10.1056/nejm199102143240701. PMID 1988827.
  25. ^ Johnstone, David E.; Sands, Milton J.; Berger, Harvey J.; Reduto, Lawrence A.; Lachman, Anthony S.; Wackers, Frans J. Th; Cohen, Lawrence S.; Gottschalk, Alexander; Zaret, Barry L. (1980-06-01). "Comparison of exercise radionuclide angiocardiography and thallium-201 myocardial perfusion imaging in coronary artery disease". American Journal of Cardiology. 45 (6): 1113–1119. doi:10.1016/0002-9149(80)90467-1. ISSN 0002-9149. PMID 7377108.
  26. ^ "Ariad CEO on Developing New Drugs". Fox Business. 2011-07-15. Retrieved 2017-11-10.
  27. ^ "Ariad CEO on the Three Drugs in the Pipeline for Cancer Treatment". Fox Business. 2011-11-10. Retrieved 2017-11-10.
  28. ^ "Ariad Pharmaceuticals Working on Cancer 'Miracle Pill'". Fox Business. 2012-08-03. Retrieved 2017-11-10.
  29. ^ "Ariad Pharmaceuticals CEO on a New Leukemia Drug". Fox Business. 2012-06-08. Retrieved 2017-11-10.
  30. ^ Chang, Kirsten (2012-06-04). "Cramer Interviews Ariad Pharma CEO". CNBC. Retrieved 2017-11-10.
  31. ^ Staff, AOL. "ARIAD Chief Executive Officer, Harvey J. Berger, M.D., Recognized as 2013 Ernst & Young Entrepreneur". AOL.com. Retrieved 2017-09-21.
  32. ^ Wire, Business (2013-06-18). "ARIAD Honored With Gold Stevie® Awards As Pharmaceutical Company Of The Year At 2013 American Business Awardssm". TheStreet. Retrieved 2017-09-25.
  33. ^ "Life Sciences & Pharmaceuticals CEO Symposium". www.yjp.org. Retrieved 2017-09-25.
  34. ^ "Palm Beach 13-year-old gets Broadway bash – and a visit from Flo Rida". palmbeachdailynews. Retrieved 2017-09-23.
  35. ^ "Alumni > Autumn 2008 | Yale Medicine". ymm.yale.edu. Retrieved 2017-11-10.
  36. ^ king-theme.com. "TWO FOR ONE: Buffalo Debut November 4th at Buffalo Dreams Festival". www.filmbuffaloniagara.com. Retrieved 2017-09-23.
  37. ^ "PET-OWNING & PARENTING". New York Post. 2003-08-17. Retrieved 2017-11-10.
  38. ^ "Nicole Elizabeth Berger Debuts Film Two for One at Napa Film Festival". I Heart Heels. 2016-11-12. Retrieved 2017-11-10.
  39. ^ "'Jukebox Hero' Gramm brings '80s to life for American Cancer Society". palmbeachdailynews. Retrieved 2017-11-10.
  40. ^ "MAD, PMP, HSS, and PBDA". New York Social Diary. 2017-03-20. Retrieved 2017-11-10.
  41. ^ "Dana-Farber Cancer Institute appoints six new members to Board of Trustees – Dana-Farber Cancer Institute | Boston, MA". www.dana-farber.org. Retrieved 2018-03-20.